349 related articles for article (PubMed ID: 22244043)
1. Molecular characterization of familial hypercholesterolemia in Spain.
Palacios L; Grandoso L; Cuevas N; Olano-Martín E; Martinez A; Tejedor D; Stef M
Atherosclerosis; 2012 Mar; 221(1):137-42. PubMed ID: 22244043
[TBL] [Abstract][Full Text] [Related]
2. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I
Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133
[TBL] [Abstract][Full Text] [Related]
3. A DNA microarray for the detection of point mutations and copy number variation causing familial hypercholesterolemia in Europe.
Stef MA; Palacios L; Olano-Martín E; Foe-A-Man C; van de Kerkhof L; Klaaijsen LN; Molano A; Schuurman EJ; Tejedor D; Defesche JC
J Mol Diagn; 2013 May; 15(3):362-72. PubMed ID: 23537714
[TBL] [Abstract][Full Text] [Related]
4. Genetic analysis of familial hypercholesterolaemia in Western Australia.
Hooper AJ; Nguyen LT; Burnett JR; Bates TR; Bell DA; Redgrave TG; Watts GF; van Bockxmeer FM
Atherosclerosis; 2012 Oct; 224(2):430-4. PubMed ID: 22883975
[TBL] [Abstract][Full Text] [Related]
5. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.
Mabuchi H; Nohara A; Noguchi T; Kobayashi J; Kawashiri MA; Inoue T; Mori M; Tada H; Nakanishi C; Yagi K; Yamagishi M; Ueda K; Takegoshi T; Miyamoto S; Inazu A; Koizumi J;
Atherosclerosis; 2014 Sep; 236(1):54-61. PubMed ID: 25014035
[TBL] [Abstract][Full Text] [Related]
6. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
[TBL] [Abstract][Full Text] [Related]
7. The genetic spectrum of familial hypercholesterolemia in south-eastern Poland.
Sharifi M; Walus-Miarka M; Idzior-Waluś B; Malecki MT; Sanak M; Whittall R; Li KW; Futema M; Humphries SE
Metabolism; 2016 Mar; 65(3):48-53. PubMed ID: 26892515
[TBL] [Abstract][Full Text] [Related]
8. Array-based resequencing for mutations causing familial hypercholesterolemia.
Chiou KR; Charng MJ; Chang HM
Atherosclerosis; 2011 Jun; 216(2):383-9. PubMed ID: 21376320
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms in LDLR, APOB, PCSK9 and other lipid related genes associated with familial hypercholesterolemia in Malaysia.
Lye SH; Chahil JK; Bagali P; Alex L; Vadivelu J; Ahmad WA; Chan SP; Thong MK; Zain SM; Mohamed R
PLoS One; 2013; 8(4):e60729. PubMed ID: 23593297
[TBL] [Abstract][Full Text] [Related]
10. Detection of mutations and large rearrangements of the low-density lipoprotein receptor gene in Taiwanese patients with familial hypercholesterolemia.
Chiou KR; Charng MJ
Am J Cardiol; 2010 Jun; 105(12):1752-8. PubMed ID: 20538126
[TBL] [Abstract][Full Text] [Related]
11. Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease.
Al-Allaf FA; Athar M; Abduljaleel Z; Taher MM; Khan W; Ba-Hammam FA; Abalkhail H; Alashwal A
Gene; 2015 Jul; 565(1):76-84. PubMed ID: 25839937
[TBL] [Abstract][Full Text] [Related]
12. Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia.
Alves AC; Etxebarria A; Soutar AK; Martin C; Bourbon M
Hum Mol Genet; 2014 Apr; 23(7):1817-28. PubMed ID: 24234650
[TBL] [Abstract][Full Text] [Related]
13. The genetic spectrum of familial hypercholesterolemia in Pakistan.
Ahmed W; Whittall R; Riaz M; Ajmal M; Sadeque A; Ayub H; Qamar R; Humphries SE
Clin Chim Acta; 2013 Jun; 421():219-25. PubMed ID: 23535506
[TBL] [Abstract][Full Text] [Related]
14. Familial hypercholesterolemia in Brazil: cascade screening program, clinical and genetic aspects.
Jannes CE; Santos RD; de Souza Silva PR; Turolla L; Gagliardi AC; Marsiglia JD; Chacra AP; Miname MH; Rocha VZ; Filho WS; Krieger JE; Pereira AC
Atherosclerosis; 2015 Jan; 238(1):101-7. PubMed ID: 25461735
[TBL] [Abstract][Full Text] [Related]
15. Genetic heterogeneity of autosomal dominant hypercholesterolemia in Mexico.
Robles-Osorio L; Huerta-Zepeda A; Ordóñez ML; Canizales-Quinteros S; Díaz-Villaseñor A; Gutiérrez-Aguilar R; Riba L; Huertas-Vázquez A; Rodríguez-Torres M; Gómez-Díaz RA; Salinas S; Ongay-Larios L; Codiz-Huerta G; Mora-Cabrera M; Mehta R; Gómez Pérez FJ; Rull JA; Rabès JP; Tusié-Luna MT; Durán-Vargas S; Aguilar-Salinas CA
Arch Med Res; 2006 Jan; 37(1):102-8. PubMed ID: 16314194
[TBL] [Abstract][Full Text] [Related]
16. [Familial hypercholesterolemia in Tunisia].
Jelassi A; Jguirim I; Najah M; Maatouk F; Ben Hamda K; Slimane MN
Pathol Biol (Paris); 2009 Jul; 57(5):444-50. PubMed ID: 19041195
[TBL] [Abstract][Full Text] [Related]
17. The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype.
Drouin-Chartier JP; Tremblay AJ; Hogue JC; Ooi TC; Lamarche B; Couture P
Metabolism; 2015 Nov; 64(11):1541-7. PubMed ID: 26371983
[TBL] [Abstract][Full Text] [Related]
18. No genetic linkage or molecular evidence for involvement of the PCSK9, ARH or CYP7A1 genes in the Familial Hypercholesterolemia phenotype in a sample of Danish families without pathogenic mutations in the LDL receptor and apoB genes.
Damgaard D; Jensen JM; Larsen ML; Soerensen VR; Jensen HK; Gregersen N; Jensen LG; Faergeman O
Atherosclerosis; 2004 Dec; 177(2):415-22. PubMed ID: 15530918
[TBL] [Abstract][Full Text] [Related]
19. Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease - A study supported by the Korean Society of Lipidology and Atherosclerosis.
Shin DG; Han SM; Kim DI; Rhee MY; Lee BK; Ahn YK; Cho BR; Woo JT; Hur SH; Jeong JO; Jang Y; Lee JH; Lee SH
Atherosclerosis; 2015 Nov; 243(1):53-8. PubMed ID: 26343872
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
